Scarica l'app Stockscreener
34.99
1.16%
-0.41
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$35.40
Aprire:
$35.77
Volume 24 ore:
2.15M
Relative Volume:
0.95
Capitalizzazione di mercato:
$5.83B
Reddito:
$1.56B
Utile/perdita netta:
$152.72M
Rapporto P/E:
38.90
EPS:
0.8994
Flusso di cassa netto:
$221.80M
1 W Prestazione:
+4.82%
1M Prestazione:
+0.63%
6M Prestazione:
+6.38%
1 anno Prestazione:
+15.17%
Intervallo 1D:
$34.87
$35.93
Intervallo di 1 settimana:
$33.20
$36.60
Portata 52W:
$25.16
$36.60
Alkermes Plc Stock (ALKS) Company Profile
Nome
Alkermes Plc
Settore
Telefono
00-353-1-772-8000
Indirizzo
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
34.99 | 5.83B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
16.46 | 52.00B | 29.85B | 776.90M | 4.35B | 0.2408 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.73 | 41.60B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.11 | 40.43B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
82.83 | 34.72B | 9.47B | 2.67B | 2.28B | 6.0218 |
UTHR
United Therapeutics Corp
|
564.94 | 23.98B | 3.18B | 1.33B | 1.04B | 27.90 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2025-11-11 | Iniziato | Truist | Buy |
| 2025-09-26 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Iniziato | Wells Fargo | Overweight |
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2025-06-17 | Aggiornamento | UBS | Neutral → Buy |
| 2025-05-28 | Iniziato | Needham | Buy |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Aggiornamento | UBS | Sell → Neutral |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-11-05 | Aggiornamento | Stifel | Hold → Buy |
| 2024-06-17 | Iniziato | TD Cowen | Buy |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-20 | Downgrade | UBS | Neutral → Sell |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Iniziato | UBS | Neutral |
| 2022-11-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Iniziato | Piper Sandler | Neutral |
| 2022-04-22 | Ripresa | Goldman | Buy |
| 2022-04-20 | Iniziato | Goldman | Buy |
| 2022-01-27 | Aggiornamento | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Iniziato | Citigroup | Neutral |
| 2021-10-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-09-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2020-02-14 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-01-31 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-31 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-01 | Downgrade | Citigroup | Buy → Neutral |
| 2018-12-19 | Downgrade | Goldman | Neutral → Sell |
| 2018-12-14 | Iniziato | Wolfe Research | Underperform |
| 2018-12-13 | Downgrade | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Iniziato | Piper Jaffray | Neutral |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-06-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Alkermes Plc Borsa (ALKS) Ultime notizie
Alkermes (ALKS) Q1 2026 Earnings Transcript - AOL.com
Alkermes plc 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ALKS) 2026-05-07 - Seeking Alpha
Alkermes Advances Brilliance NT2 Phase 3 Trial, Raising Interest in Narcolepsy Market - TipRanks
Alkermes price target raised to $48 from $42 at UBS - TipRanks
Alkermes price target raised to $50 from $45 at Needham - TipRanks
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises - MSN
Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results - Benzinga
Alkermes Q1 2026 earnings preview - MSN
Did Rising Revenue but New Net Loss Just Shift Alkermes' (ALKS) Investment Narrative? - Sahm
Alkermes plc (NASDAQ:ALKS) Q1 2026 Earnings Call Transcript - Insider Monkey
Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company (ALKS) - Seeking Alpha
Alkermes Q1 2026 slides: Avadel deal drives revenue beat By Investing.com - Investing.com Australia
Stifel raises Alkermes stock price target on orexin pipeline progress - Investing.com UK
Alkermes plc Q1 2026 10-Q: Financial Highlights, Risk Factors, and Forward-Looking Statements - Minichart
Stifel raises Alkermes stock price target on orexin pipeline progress By Investing.com - Investing.com Nigeria
Alkermes stock hits 52-week high at $36.48 By Investing.com - Investing.com South Africa
Alkermes Earnings Call: LUMRYZ Momentum Drives Growth - TipRanks
Alkermes plc reports first quarter 2026 financial results - MSN
Insider Sell: David Gaffin Sells Shares of Alkermes PLC - GuruFocus
Alkermes plc Q1 2026 Earnings Call Summary - Yahoo Finance
Avadel deal shifts Alkermes (NASDAQ: ALKS) to Q1 loss on higher costs - Stock Titan
Alkermes stock hits 52-week high at $36.48 - Investing.com
Alkermes Q1 2026 Earnings Call Transcript - MarketBeat
ALKS: Q1 2026 delivered robust sales growth, expanded sleep medicine presence, and advanced orexin pipeline - TradingView
Alkermes Q1 2026 slides: Avadel deal drives revenue beat - Investing.com
Alkermes plc Reports First Quarter 2026 Financial Results - BioSpace
Earnings call transcript: Alkermes Q1 2026 results beat expectations, stock rises - Investing.com
Alkermes Plc reports results for the quarter ended March 31Earnings Summary - TradingView
Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Alkermes Swings to Q1 Loss, Revenue Rises; Reiterates 2026 Revenue Guidance - marketscreener.com
Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo! Finance Canada
Alkermes plc (NASDAQ:ALKS) Reports Mixed Q1 Results, Beats Revenue Forecasts but Posts Wider Than Expected Loss - ChartMill
Alkermes rises as quarterly loss narrows, tops estimates By Investing.com - Investing.com Nigeria
Q1 2026 Alkermes Plc Earnings Call Transcript - GuruFocus
Alkermes rises as quarterly loss narrows, tops estimates - Investing.com
(ALKS) Alkermes Expects 2026 Revenue Range $1.73B$1.84B, vs. FactSet Est of $1.80B - marketscreener.com
Earnings Flash (ALKS) Alkermes Posts Q1 Net Loss $0.40 a Share, vs. FactSet Est of $0.58 Loss - marketscreener.com
Alkermes reports Q1 2026: Revenues $392.9M, GAAP loss $66.5M, Adjusted EBITDA $80.3M - TradingView
Alkermes: Q1 Earnings Snapshot - Barchart
Avadel deal drives Alkermes (NASDAQ: ALKS) Q1 growth and 2026 EBITDA upgrade - Stock Titan
Alkermes (ALKS) CLO David Gaffin sells 2,034 shares, retains 231,558 - Stock Titan
Insider sales reported for Alkermes (NASDAQ: ALKS) on Form 144 — three transactions listed - Stock Titan
Alkermes Plc Azioni (ALKS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.49%
1.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):